Etoricoxib Generic

Generic Etoricoxib (sometimes also called generic Arcoxia) containing the active ingredient Etoricoxib is a medications for the treatment of Inflammation. Generic Etoricoxib is offered and sold on the pharmaceutical market in Denmark as a lower-cost generic equivalent of a more expensive original (branded) prescription drug called Arcoxia. Both original Arcoxia and its cheaper generic Etoricoxib equivalent contains the labelled quantity of same active ingredient with the equal quality. Etoricoxib belongs to a class of medications called Anti-inflammatory. As well as Arcoxia, generic Etoricoxib is a prescription medication that is used to treat Inflammation and is available in drug tablet form and dosage amounts of 60, 90, 120 mg. Below you can find and compare prices for generic Etoricoxib at many pharmacies that offer you to buy generic Etoricoxib in Denmark online with delivery to your doors. Find a suitable online pharmacy with the best Etoricoxib prices and deals.
Prices for tablets of Etoricoxib 90mg
Prices for Generic Etoricoxib in denmark Click to change region.
Etoricoxib Generic
Etoricoxib Generic
90mg, 30 pills
354.86 295.7 DKK Go to store
Etoricoxib Generic
Etoricoxib Generic
90mg, 60 pills
664.47 553.71 DKK Go to store
Etoricoxib Generic
Etoricoxib Generic
90mg, 90 pills
951.42 792.84 DKK Go to store
Etoricoxib Generic
Etoricoxib Generic
90mg, 120 pills
1215.73 1013.09 DKK Go to store
Etoricoxib Generic
Etoricoxib Generic
90mg, 180 pills
1782.09 1485.06 DKK Go to store
Etoricoxib Generic
Etoricoxib Generic
90mg, 240 pills
2340.9 1950.74 DKK Go to store


Active ingredient : Etoricoxib Manufactured by : Various
Treatment: Inflammation Dosage : 60, 90, 120 mg

Etoricoxib Medicine Information

One of the important problems of modern medicine, in particular, orthopedics and traumatology, is the treatment of chronic joint pain. According to separate publications, chronic pain affects 20 to 30% of the population of the United States and Europe (more than 75 million people). At the same time, up to 60% of the population over the age of 60 suffer from pain more than 1 year, one in five patients suffers from chronic pain for more than 20 years.

Among the typical, most common causes of such joint pains, osteoarthritis of the joints - a degenerative-dystrophic pathology, accompanied by severe pain syndrome, periodic exacerbations, restriction of function, should be noted. Despite the variety of predisposing factors and clinical variants of the disease, described as primary or secondary arthrosis, researchers recognize the significant role of inflammation in the pathogenesis of the process under consideration. Given this, the use of non-steroidal anti-inflammatory drugs (NSAIDs) is a universally recognized component of the therapy of osteoarthritis. This is due to both the anti-inflammatory and analgesic effects of the drugs in this group. However, despite the creation of more and more new and effective NSAIDs, the problem of chronic pain can not be recognized as solved, this is indicated by the very number of patients and the duration of the pain syndrome, as mentioned above. Moreover, many of the patients with chronic articular pain are dissatisfied with the available treatment options and would like to find a more effective remedy. Do not forget about the specific frequency of complications associated with the use of NSAIDs, which makes it important to analyze not only their effectiveness, but also the safety of use.

That is why the development of new drugs in this group is of direct interest to practitioners and new hopes for the prospects of treatment of chronic pain syndromes.

Etoricoxib refers to drugs that selectively block cyclooxygenase (COX-2), an inducible enzyme isoform that is activated in pain and inflammation. It is believed that COX-1 is constantly expressed in normal tissues, including in the tissues of the kidneys and in the endothelium, as a result of normal vital activity of the cells. In contrast, COX-2 is induced by pro-inflammatory cytokines and its amount rises in inflamed tissues. In this regard, there are certain expectations that selective NSAIDs will act more purposefully, and reducing their impact on COX-1 will reduce the incidence of complications.

According to its acid-base properties, Etoricoxib is the base as opposed to non-selective NSAIDs, which are weak organic acids. This factor should be taken into account when analyzing the safety of the drug in terms of the likelihood of gastrointestinal complications.

According to its pharmacokinetic and pharmacodynamic characteristics, Etoricoxib is well suited for the treatment of pain and inflammation. It is rapidly absorbed with bioavailability at oral intake of about 100%. The pharmacokinetics of Etoricoxib is linear and proportional to the dose, the half-life period allows to prescribe the drug once a day. As the results of clinical studies show, the action of Etoricoxib begins quickly (according to the developers, after 24 minutes) and lasts up to 24 hours. The time to reach the maximum concentration of Etoricoxib in plasma (Tmax) is 1 hour, and the elimination half-life is 22 hours.

Rapidly developing, long-term action of Etoricoxib, the ability to influence both the inflammatory component and directly to the pain caused a very wide range of its application. Thus, according to the instructions for the use of the drug, which has already been reported in special publications, Etoricoxib can be used as a symptomatic therapy for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis, and to alleviate acute and chronic pain.

The dosage of the drug differs depending on the nosology and the severity of the pain syndrome. So, with osteoarthritis, the recommended dose is 60 mg with a single dose. With rheumatoid arthritis and ankylosing spondylitis it is recommended to take 90 mg of the drug, and in acute gouty arthritis in the acute period - 120 mg once a day. It is noted that the duration of administration of Etoricoxib in a dose of 120 mg should not exceed 8 days.

With pain syndrome, the average therapeutic dose is estimated as 60 mg per day for a single dose. However, with acute pain, the dose of Etoricoxib can be increased to 120 mg once a day (as mentioned above, no more than 8 days). A variety of available dosages (tablets of 60, 90 and 120 mg) allows you to take into account all of the listed options.

In terms of preventing possible complications from both the gastrointestinal tract and the cardiovascular system, the doses of the drug should not exceed those specified in the instructions, and patients need dynamic monitoring by the attending physician. In particular, the dose for the treatment of osteoarthritis should not exceed 60 g per day. And in connection with the potential increase in risks for the cardiovascular system with long-term use of high doses of Etoricoxib, the lowest effective doses of the drug should be used as short as possible.

Like any new drug, Etoricoxib has undergone a series of comparative studies with known drugs of a similar purpose. So, in order to assess the overall analgesic effect, tolerability and safety profile of the selective COX-2 Etoricoxib inhibitor in patients with postoperative pain after orthopedic surgery, a clinical study comparing Etoricoxib with placebo and naproxen sodium was performed in patients with pain syndrome after endoprosthesis surgery hip joint or knee arthroplasty. This study showed the high efficacy of Etoricoxib and a completely satisfactory safety profile. Other studies have shown a high degree of effectiveness of Etoricoxiba with osteoarthritis, chronic lumbar pain and rheumatoid arthritis.

The data published in this article allow one to judge the prospects of the use of Etoricoxib in the practice of an orthopedist traumatologist for the relief of acute and chronic pain caused not only by osteoarthrosis but also by rheumatoid and acute gouty arthritis. There are also data on the effectiveness of its use in postoperative pain. It is very beneficial from a clinical point of view, rapid development of the analgesic effect and duration of action, which allows the drug to be used once a day. Further analysis of the results of the use of Etoricoxib will allow us to more accurately judge its capabilities and clarify the place of this drug in the general spectrum of therapeutic options for the relief of acute and chronic joint pain.

Etoricoxib summary

Etoricoxib and its structural analogues is the last representative of non-steroidal anti-inflammatory drugs. Reviews of doctors regarding the drug are mostly positive. It is characterized as an anti-inflammatory and analgesic substance that can alleviate the condition and improve the quality of life in chronic and acute joint pain caused by ankylosing spondylitis, rheumatoid arthritis, acute gout arthritis.

This medication was tested on 45 000 patients. This is the most researched drug in its group. Today, there are studies on the use of malignant tumors, back pain and migraines.

All analogues on the basis of Etoricoxib cropped pain attack after 24 minutes after administration. The minimum dosage is enough to achieve analgesic effect for a day.

Unlike its substitutes Etoricoxib does not cause irritation of the intestinal mucosa and stomach. The risk of flatulence, diarrhea and nausea is minimized. Feedback from patients and doctors confirm its safety for the digestive system.

Instructions for use and method of administration

The drug's dosage is 60-120 mg. one time in 24 hours.

The doctor should take into account the nature of the disease and prescribe the optimal dose, if the patient has problems with the functioning of the liver. The dose, recommended by the manufacturer - 60 mg.

The drug is prescribed with caution to patients who have a history of severe somatic diseases, gastrointestinal ulcer, and at the moment there are hypertension, diabetes, swelling.

During therapy in these cases, control of blood pressure is required. Measurements must be taken in the first 2 weeks. Further supervision at the discretion of the attending physician.

It is important to periodically analyze the performance of the kidneys and liver. If there is an increase in the level of enzyme activity the treatment should be suspended.

It is forbidden to take Etoricoxib simultaneously with other nonsteroidal anti-inflammatory drugs.

During the therapeutic course, patients are recommended to be careful when working with complex mechanisms and when driving vehicles, as feedback is received about the attacks of dizziness, weakness and drowsiness.

Indications for use

Etoricoxib can help you in various cases:

  • defeat of cartilaginous tissue as a result of the development of osteoarthritis;
  • systemic rheumatoid arthritis, which affects connective tissue;
  • pain in the knee joint, ankle, fingers, legs, caused by acute gout arthritis;
  • long-term chronic inflammation of the vertebral column joints, diagnosed as ankylosing spondylitis.

Etoricoxib substitutes

Arcoxia analog is suitable for use in a wider range. For example, to reduce pain after dental surgery.

Arcoxia is produced by pharmaceutical factories in the Netherlands and the USA.

Etoricoxib has no other substitutes with similar composition.

Use during pregnancy, lactation and in childhood

This drug is prohibited for women during and throughout the period of child bearing due to the risk of violations in the development of the child. The active substance can penetrate into breast milk.

It is not recommended to use Etoricoxib when planning a pregnancy, as presumably has an effect on fertility.

Not recommended to use this drug in childhood due to lack of data and lack of research on the effects on the body.

Ethoricoxib are prohibited under the following conditions:

  • violation of the process of blood coagulability;
  • the minimum period after aortocoronary bypass surgery;
  • pathology of the liver and acute failure in the functioning of this body;
  • arterial hypertension expressed;
  • diseases of the intestines, accompanied by inflammation of the mucous membranes;
  • ulcerative lesion and bleeding in the lumen of the gastrointestinal tract;
  • cardiac ischemia;
  • high sensitivity to the main active substance;
  • pathology of peripheral arteries;
  • acute heart failure, classified by NYHA.

Side effects

Etoricoxib and its substitutes can cause a number of negative reactions. Feedback confirms this fact:

  • sleep disturbance;
  • bloating;
  • confusion of consciousness;
  • conjunctivitis;
  • fluid retention;
  • muscle cramps;
  • change in urine analysis;
  • hives;
  • gastritis;
  • infection of the upper sections of the dasgulatory pathways;
  • dyspnea;
  • myalgia;
  • myocardial infarction;
  • weight gain;
  • increased peristalsis;
  • hallucinations;
  • hepatitis;
  • changes in appetite after taking the drug;
  • weakness;
  • nose bleed;
  • atrial fibrillation;
  • arthralgia;
  • cough;
  • increased blood pressure;
  • dry mouth;
  • epigastric pain;
  • blurred vision;
  • violation of sleep;
  • anxiety;
  • esophagitis;
  • bronchospasm;
  • heart failure;
  • vomiting and nausea;
  • depression;
  • reversible renal failure;
  • swelling of the face;
  • impaired cerebral circulation;
  • proteinuria;

Etoricoxib and Arcoxia can cause other side effects.

Patient feedback indicates good tolerability of the drug in most cases.


At this time there is no evidence of an overdose of these medicines. Multiple and prolonged use does not cause toxic poisoning.

Possible symptoms: increased side effects from the cardiovascular system, digestive organs and kidneys.

Treatment with a higher dosage of the drug Etoricoxib is aimed at eliminating symptoms.

Reviews about this drug substance of researchers exclude the risk of serious consequences.